RESUMEN
AIMS/HYPOTHESIS: IFN-gamma, together with other inflammatory cytokines such as IL-1beta and TNF-alpha, contributes to beta cell death in type 1 diabetes. We analysed the role of the transcription factor interferon regulatory factor (IRF)-1, a downstream target of IFN-gamma/signal transducer and activator of transcription (STAT)-1, in immune-mediated beta cell destruction. METHODS: Islets from mice lacking Irf-1 (Irf-1 (-/-)) and control C57BL/6 mice were transplanted in overtly diabetic NOD mice. Viability and functionality of islets were evaluated in vitro. Chemokine expression by Irf-1 (-/-) islets and INS-1E cells transfected with Irf-1 short interfering RNA (siRNA) was measured by real-time PCR as well as in functional assays in vitro. RESULTS: IRF-1 deletion in islets was associated with higher prevalence of primary non-function (63% vs 25%, p Asunto(s)
Células Secretoras de Insulina/fisiología
, Factor 1 Regulador del Interferón/metabolismo
, Factores de Transcripción/metabolismo
, Animales
, Muerte Celular
, Supervivencia Celular
, Cartilla de ADN
, Glucosa/farmacología
, Supervivencia de Injerto/inmunología
, Insulina/metabolismo
, Secreción de Insulina
, Células Secretoras de Insulina/citología
, Células Secretoras de Insulina/inmunología
, Factor 1 Regulador del Interferón/deficiencia
, Factor 1 Regulador del Interferón/genética
, Trasplante de Islotes Pancreáticos/métodos
, Ratones
, Ratones Endogámicos C57BL
, Ratones Endogámicos NOD/cirugía
, Ratones Noqueados
, Reacción en Cadena de la Polimerasa/métodos
, ARN Interferente Pequeño/genética
, Transfección
, Trasplante Homólogo/inmunología
, Trasplante Homólogo/fisiología
RESUMEN
Islet transplantation is a promising treatment in type 1 diabetes, but the need for chronic immunosuppression is a major hurdle to broad applicability. Ex vivo introduction of agents by lentiviral vectors-improving beta-cell resistance against immune attack-is an attractive path to pursue. The aim of this study was to investigate whether dissociation of islets to single cells prior to viral infection and reaggregation before transplantation would improve viral transduction efficacy without cytotoxicity. This procedure improved transduction efficacy with a LV-pWPT-CMV-EGFP construct from 11.2 +/- 4.1% at MOI 50 in whole islets to 80.0 +/- 2.8% at MOI 5. Viability (as measured by Hoechst/PI) and functionality (as measured by glucose challenge) remained high. After transplantation, the transfected pseudoislet aggregates remained EGFP positive for more than 90 days and the expression of EGFP colocalized primarily with the insulin-positive beta-cells. No increased vulnerability to immune attack was observed in vitro or in vivo. These data demonstrate that dispersion of islets prior to lentiviral transfection and reaggregation prior to transplantation is a highly efficient way to introduce genes of interest into islets for transplantation purposes in vitro and in vivo, but the amount of beta-cells needed for normalization of glycemia was more than eightfold higher when using dispersed cell aggregates versus unmanipulated islets. The high price to pay to reach stable and strong transgene expression in islet cells is certainly an important cell loss.